News & Analysis on Clinical Trial Services & Contract Research And Development
The launch of newer technology products with a wide range of applications and the facility to deliver proteins, peptides, and large molecules is expected to rake in market revenues, according to a new report from market analysts Frost & Sullivan.
Strasbourg, France-based Aventis has signed a research, option and license agreement with Vivalis of the USA for the manufacture of vaccine candidates using avian stem cell technology.
Despite a testing global economic climate, sales remained steady and earnings before interest and taxes rose for German speciality chemicals company Degussa in the first quarter of 2003. But guarded optimism remains for 2003.